Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Brain Neoplasms × Vemurafenib × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1 CNS 1

Conditions

Melanoma 24 Neoplasm Metastasis 7 Neoplasms 6 Lymphoma, Non-Hodgkin 4 Leukemia, Hairy Cell 4 Colorectal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Wilms Tumor 2 Thyroid Neoplasms 2 Thyroid Cancer, Papillary 2 Sarcoma, Ewing 2 Sarcoma 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2 Osteosarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroblastoma 2 Multiple Myeloma 2 Histiocytosis, Langerhans-Cell 2 Hepatoblastoma 2 Glioma 2 Ependymoma 2 Central Nervous System Neoplasms 2 Xanthogranuloma, Juvenile 1 Urinary Bladder Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Skin Neoplasms 1 Sarcoma, Clear Cell 1 Relapsed Pediatric Solid Tumor 1 Rare Tumour 1

Interventions

Temozolomide 55 Bevacizumab 51 Radiotherapy 34 Radiosurgery 24 Carboplatin 20 pembrolizumab 15 Irinotecan 14 Etoposide 14 Nivolumab 13 Cisplatin 13 Carmustine 13 Cyclophosphamide 12 Pemetrexed 11 Ipilimumab 11 Erlotinib Hydrochloride 11 Magnetic Resonance Spectroscopy 10 Surgical Procedures, Operative 9 Lapatinib 9 Capecitabine 9 Topotecan 8 Thalidomide 8 Aminolevulinic Acid 8 Lomustine 7 Gefitinib 7 Filgrastim 7 trametinib 6 osimertinib 6 encorafenib 6 binimetinib 6 Trastuzumab 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03430947 2023-09-14

RadioCoBRIM

Technische Universität Dresden

Phase 2 Terminated

CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡